[go: up one dir, main page]

WO1996024361A1 - Procede destine a soulager ou a traiter des irritations epidermiques - Google Patents

Procede destine a soulager ou a traiter des irritations epidermiques Download PDF

Info

Publication number
WO1996024361A1
WO1996024361A1 PCT/US1996/001669 US9601669W WO9624361A1 WO 1996024361 A1 WO1996024361 A1 WO 1996024361A1 US 9601669 W US9601669 W US 9601669W WO 9624361 A1 WO9624361 A1 WO 9624361A1
Authority
WO
WIPO (PCT)
Prior art keywords
hyaluronic acid
acid salt
skin
stump
discomfort
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1996/001669
Other languages
English (en)
Inventor
Boaz Amit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Savient Pharmaceuticals Inc
Original Assignee
Savient Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savient Pharmaceuticals Inc filed Critical Savient Pharmaceuticals Inc
Priority to AU49174/96A priority Critical patent/AU4917496A/en
Publication of WO1996024361A1 publication Critical patent/WO1996024361A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid

Definitions

  • NaHA Sodium hyaluronate
  • NaHA is present in various connective tissues of animals, such as skin and cartilage. Some organs are specifically rich in HA, such as the umbilical cord, synovial fluid, the vitreous humor, and rooster combs. In addition, NaHA is produced by various microorganisms, such as Streptococci Type A and C.
  • the role of NaHA is to bind water and retain the tonicity and elasticity of the tissue.
  • the viscous NaHA solution serves as a lubricant to provide a protective environment to the cells.
  • synovial fluid acts to lubricate effectively the surfaces of bones that are in frictional contact to form joints (3) .
  • NaHA is used by means of interarticular injections, as adjuvant in the therapy of degenerative and/or inflammatory diseases of the articular synovial sheaths (2) .
  • NaHA is widely used in ophthalmic surgery, due to its elasto-viscous properties and rheologic properties (1) .
  • NaHA is used in cataract operations that are associated with intraocular lens implantation, as well as glaucoma and corneal transplant operations and more generally in any traumatopathy involving retinal detachment (2) .
  • diluted solutions of NaHA less than 0.2%w/v, may be used to relieve symptoms of lacrimal film diseases (2) .
  • the instant invention relates to a method of relieving and preventing discomfort experienced by an amputee upon wearing a prosthetic device on a stump of an amputated limb.
  • the instant invention relates to method of relieving and preventing discomfort associated with chafing of skin.
  • the subject invention provides a method of relieving and preventing discomfort experienced by an amputee upon wearing a prosthetic device on a stump of an amputated limb while permitting continued wearing by the amputee of the prosthetic device which comprises applying to the surface of the stump an amount of a hyaluronic acid salt effective to relieve such discomfort prior to placing the prosthetic device on the stump and then placing the prosthetic device on the stump without removing the hyaluronic acid salt.
  • the subject invention further provides a method of relieving and preventing discomfort associated with chafing of skin which comprises applying to the surface of the chafed skin an amount of a hyaluronic acid salt effective to relieve such discomfort .
  • hyaluronic acid salt encompasses hyaluronic acid or any of its salts.
  • the sodium salt of hyaluronic acid is especially preferred but other salts are also envisaged, see e.g. coassigned U.S. Patent No. 4,784,991.
  • the hyaluronic acid salt may be produced from any source including bacteria, cockscombs or umbilical cord and may be produced by any purification procedure known in the art.
  • the preferred hyaluronic acid salt was produced essentially as described in coassigned U.S. Patent Nos . 4,780,414 and 4,784,990.
  • NaHA may also be produced as described in U.S. Patent No. 4,141,973 (Balazs) or EPO Patent Publication No. 144019 (Brown et al. ) .
  • the subject invention provides a method of relieving and preventing discomfort experienced by an amputee upon wearing a prosthetic device (artificial limb) on a stump of an amputated limb while permitting continued wearing by the amputee of the prosthetic device which comprises applying to the surface of the stump an amount of a hyaluronic acid salt effective to relieve such discomfort prior to placing the prosthetic device on the stump and then placing the prosthetic device on the stump without removing the hyaluronic acid salt.
  • skin lesion encompasses skin redness or soreness, painful tissue, dermatologically irritated skin, blisters and open wounds.
  • the skin lesion is a skin wound and the hyaluronic acid salt is sodium hyaluronate.
  • hyaluronic acid salts may be used to treat skin lesions on the stump of an amputated limb.
  • hyaluronic acid salts may be used prophylactically to prevent the formation of skin lesions on the stump of an amputated limb.
  • the subject invention further provides a method of relieving and preventing discomfort associated with chafing of the skin which comprises applying to the surface of the chafed skin an amount of a hyaluronic acid salt effective to relieve such discomfort.
  • the chafed skin comprises a chafed upper leg and the hyaluronic acid salt is sodium hyaluronate.
  • the subject invention also provides a use of an effective amount of a hyaluronic acid salt in the preparation of a composition for relieving and preventing discomfort experienced by an amputee upon wearing a prosthetic device on a stump of an amputated limb while permitting continued wearing by the amputee of the prosthetic device which comprises applying to the surface of the stump an amount of the composition effective to relieve and prevent such discomfort prior to placing the prosthetic device on the stump, and then placing the prosthetic device on the stump without removing the composition.
  • the subject invention additionally provides a use of an effective amount of a hyaluronic acid salt in the preparation of a composition for relieving and preventing discomfort associated with chafing of skin which comprises applying to the surface of the chafed skin an amount of the composition effective to relieve and prevent such discomfort.
  • the hyaluronic acid salt may be chemically modified or cross-linked in any manner, see for example U.S. 4,957,744 or U.S. 4,713,448, as long as the product is effective in the claimed use and can be used to relieve discomfort.
  • the hyaluronic acid salt solution of the subject invention may have a concentration of from 0.05% to 5 % and preferably from 0.1% to 2%.
  • the most preferred concentration of the hyaluronic acid salt solution to be used is from 0.1% to 1%.
  • the molecular weight of the hyaluronic acid salt to be utilized may be from 30,000 to 13 million daltons and preferably from 300,000 to 2,000,000 daltons.
  • Hyaluronic acid salts of various molecular weights are well known in the art; see for example EP Patent Publication 197718.
  • the most preferred hyaluronic acid salt has a molecular weight of from 500,000 to 1,500,000 daltons.
  • the hyaluronic acid salt solution may be administered with or without preservatives; any suitable preservative known in the art may be used.
  • the hyaluronic acid salt solution has a concentration of about 0.5%, a molecular weight of between 700,000 to 1,500,000 daltons and comprises Germall and Phenonip preservatives.
  • the subject invention further provides an article of manufacture comprising packaging material and a hyaluronic acid salt contained within said packaging material, wherein said hyaluronic acid salt is present in an amount effective for relieving discomfort on a stump of an amputated limb and wherein said packaging material comprises a notice which indicates that said hyaluronic acid salt can be used for relieving such discomfort.
  • the subject invention also provides an article of manufacture comprising packaging material and a hyaluronic acid salt contained within said packaging material, wherein said hyaluronic acid salt is present in an amount effective for relieving discomfort caused by chafed skin and wherein said packaging material comprises a notice which indicates that said hyaluronic acid salt can be used for relieving discomfort caused by chafing of the skin.
  • the skin lesions were apparently the result of the abrasive effect of the prosthesis on the stump and/or friction between the prosthesis and the stump and/or chafing, pressure and perspiration (sweating) .
  • the skin lesions consisted of painful, red, infected wounds lacking skin. As a result of the wounds, the subject could not wear his prosthesis.
  • AMPU-BALMTM contains benzoin, methyl salicylate, phenol (0.30%) and Mutton-Tallow (Southern Prosthetic Supply Co.) , and it healed the wounds at a very slow rate, while the subject continued to have discomfort. Thus, the success of AMPU-BALMTM was limited.
  • the subject was then provided with a solution of NaHA, produced essentially as described for "cosmetic grade" sodium hyaluronate in coassigned U.S. Patent Nos. 4,780,414 and 4, 784, 990.
  • the NaHA solution consisted of:
  • Germall and Phenonip are preservatives; Germall is commercial preparation of imidazolidinylurea and Phenonip is a mixture of various parabens (methyl, propyl, etc.)
  • the soldiers were provided with a solution of NaHA as described above in Example 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Prostheses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne un procédé servant à soulager et à prévenir les sensations de malaise que ressent un amputé porteur d'une prothèse sur un moignon d'un membre amputé, ainsi qu'un procédé servant à soulager et à prévenir le malaise associé à l'irritation provoquée par le frottement sur l'épiderme.
PCT/US1996/001669 1995-02-10 1996-02-07 Procede destine a soulager ou a traiter des irritations epidermiques Ceased WO1996024361A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU49174/96A AU4917496A (en) 1995-02-10 1996-02-07 Method for relieving or treating skin discomfort

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38610095A 1995-02-10 1995-02-10
US08/386,100 1995-02-10

Publications (1)

Publication Number Publication Date
WO1996024361A1 true WO1996024361A1 (fr) 1996-08-15

Family

ID=23524155

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/001669 Ceased WO1996024361A1 (fr) 1995-02-10 1996-02-07 Procede destine a soulager ou a traiter des irritations epidermiques

Country Status (4)

Country Link
AU (1) AU4917496A (fr)
IL (1) IL116754A0 (fr)
WO (1) WO1996024361A1 (fr)
ZA (1) ZA961058B (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4784991A (en) * 1986-03-14 1988-11-15 Bio-Technology General Corp. Heavy metal salts of hyaluronic acid and their use as antimicrobial agents
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
EP0552593A1 (fr) * 1992-01-20 1993-07-28 SOCIETA'INDUSTRIA FRAMACEUTICA ITALIANA S.p.A. Utilisation d'acide hyaluronique comme lubrifiant pour prothèses oculaires
GB2280372A (en) * 1993-07-28 1995-02-01 Johnson & Johnson Medical Composite surgical material

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US4784991A (en) * 1986-03-14 1988-11-15 Bio-Technology General Corp. Heavy metal salts of hyaluronic acid and their use as antimicrobial agents
EP0552593A1 (fr) * 1992-01-20 1993-07-28 SOCIETA'INDUSTRIA FRAMACEUTICA ITALIANA S.p.A. Utilisation d'acide hyaluronique comme lubrifiant pour prothèses oculaires
GB2280372A (en) * 1993-07-28 1995-02-01 Johnson & Johnson Medical Composite surgical material

Also Published As

Publication number Publication date
IL116754A0 (en) 1996-05-14
ZA961058B (en) 1996-08-29
AU4917496A (en) 1996-08-27

Similar Documents

Publication Publication Date Title
Huynh et al. Hyaluronic acid applications in ophthalmology, rheumatology, and dermatology
US4983585A (en) Viscoelastic fluid for use in surgery and other therapies and method of using same
Van Valburg et al. Joint distraction in treatment of osteoarthritis: a two-year follow-up of the ankle
US5156839A (en) Viscoelastic fluid for use in spine and general surgery and other surgery and therapies and method of using same
CA2266811C (fr) Methode et composition pour le traitement de blessures
EP0167363B1 (fr) Glycosaminoglycanes réticulés et leur utilisation
US4486416A (en) Protection of human and animal cells subject to exposure to trauma
US5492936A (en) Bimodal molecular weight hyaluronate formulations and methods for using same
Balazs Hyaluronan as an ophthalmic viscoelastic device
JP7074951B2 (ja) 注入可能な充填剤として及びコラーゲン成長のための足場として有用な水中シリコーン油型組成物
JP5646446B2 (ja) 医療用化合物あるいは医療用製品を作成するための生体適合性ポリマーの使用方法
JPH11500032A (ja) 生分解性眼シールド
US20240358743A1 (en) Cosmetic/dermatological composition
JP2009515921A (ja) デクスパンテノール、カルシウムイオン、およびリン酸塩を含まない薬学的組成物、ならびにカルシウムキレート剤および眼科的に適合性の粘性調節剤の使用
EP1814518A1 (fr) Composition viscoelastique a trois polymeres naturels
US11376276B2 (en) Lubricating block copolymers and their use as biomimetic boundary lubricants
EP0875248B1 (fr) Utilisation d'acide hyaluronique dans la fabrication d'un médicament utile en tant que liquide de lavage intra-articulaire
WO1989000044A1 (fr) Larme artificielle
JPH08503701A (ja) 眼科用溶液および使用方法
EP1793836A2 (fr) Compositions ophtalmiques comprenant un lubrifiant, un agent deturgescent, ainsi qu'un glycosaminoglycane et methodes d'utilisation de ces dernieres
WO1996024361A1 (fr) Procede destine a soulager ou a traiter des irritations epidermiques
EP0359766A4 (en) Improved viscoelastic fluid for ophthalmic surgery and method of using same
AU2002356300B2 (en) Cosmetic scar management composition
EP0477833A1 (fr) Composition pour utilisation thérapeutique et/ou cosmétique pour le traitement des maladies de la circulation et pour les traitements aux médicaments esthétiques
EP0552593A1 (fr) Utilisation d'acide hyaluronique comme lubrifiant pour prothèses oculaires

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase